MA48723A - Procédé de production d'anticorps multispécifiques - Google Patents

Procédé de production d'anticorps multispécifiques

Info

Publication number
MA48723A
MA48723A MA048723A MA48723A MA48723A MA 48723 A MA48723 A MA 48723A MA 048723 A MA048723 A MA 048723A MA 48723 A MA48723 A MA 48723A MA 48723 A MA48723 A MA 48723A
Authority
MA
Morocco
Prior art keywords
production process
antibody production
multispecific antibody
multispecific
production
Prior art date
Application number
MA048723A
Other languages
English (en)
Inventor
Ulrich Goepfert
Hubert Kettenberger
Andrea Osterlehner
Wolfgang Paul
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA48723A publication Critical patent/MA48723A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA048723A 2017-03-10 2018-03-07 Procédé de production d'anticorps multispécifiques MA48723A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17160415 2017-03-10

Publications (1)

Publication Number Publication Date
MA48723A true MA48723A (fr) 2020-04-08

Family

ID=58266981

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048723A MA48723A (fr) 2017-03-10 2018-03-07 Procédé de production d'anticorps multispécifiques

Country Status (18)

Country Link
US (2) US20200216553A1 (fr)
EP (1) EP3592767A1 (fr)
JP (2) JP7021245B2 (fr)
KR (2) KR20190124270A (fr)
CN (1) CN110402253B (fr)
AU (1) AU2018232698B2 (fr)
BR (1) BR112019016970A2 (fr)
CA (1) CA3052357A1 (fr)
CL (1) CL2019002521A1 (fr)
CR (1) CR20190397A (fr)
IL (1) IL268470A (fr)
MA (1) MA48723A (fr)
MX (1) MX2019010575A (fr)
NZ (1) NZ756132A (fr)
PE (1) PE20191360A1 (fr)
RU (1) RU2750721C2 (fr)
SG (1) SG11201908127WA (fr)
WO (1) WO2018162517A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
WO2016087416A1 (fr) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
WO2017055542A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
EP3856789A4 (fr) * 2018-09-28 2022-08-17 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène comprenant une région variable d'anticorps modifiée
CA3130546A1 (fr) 2019-03-29 2020-10-08 Tilman Schlothauer Procede de generation d'une cellule exprimant fcrn par integration ciblee de multiples cassettes d'expression dans une organisation definie
EP3966332A4 (fr) 2019-05-07 2023-01-25 Amgen, Inc. Vecteurs et systèmes d'expression pour produire des protéines recombinées
MX2021015536A (es) 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa proteina mediante integracion dirigida usando acido ribonucleico mensajero (arnm) de cre.
CN114008081A (zh) 2019-06-19 2022-02-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生二价双特异性抗体表达细胞的方法
WO2020254352A1 (fr) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Procédé de génération d'une cellule exprimant un anticorps trivalent par intégration ciblée de multiples cassettes d'expression dans une organisation définie
JP7572977B2 (ja) 2019-06-19 2024-10-24 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
AU2020297940A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
EP4650440A1 (fr) 2023-02-17 2025-11-19 FUJIFILM Corporation Procédé de production d'une cellule, procédé de production d'un anticorps multispécifique, ensemble de vecteurs, cellule de mammifère, cellule cho et procédé de production d'un groupe de cellules

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0368926A4 (en) 1987-07-16 1991-11-27 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (fr) 1987-07-24 2001-05-22 Randy R. Robinson Assemblage modulaire de genes d'anticorps, anticorps prepares de cette facon, ainsi que leur usage
EP0319206A3 (fr) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Amplification des gènes
WO1989010959A1 (fr) 1988-05-06 1989-11-16 Codon Super-transformants pour taux eleves d'expression dans des cellules eucaryotiques
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9114468D0 (en) 1991-07-04 1991-08-21 Wellcome Found Antibody production
EP0604580A1 (fr) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab') 2?
EP0569678A3 (fr) 1992-03-13 1994-10-26 Yeda Res & Dev Cellules transfectées avec deux gènes codant pour le CMH, utilisées comme vaccins cellulaires pour la prévention immunitaire de métastases.
US6482919B2 (en) * 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP4098355B2 (ja) 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
WO1995017513A1 (fr) 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation de champignons filamenteux
US5719050A (en) 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5726041A (en) 1995-08-30 1998-03-10 Gentest Corporation Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene
WO1998008934A1 (fr) 1996-08-30 1998-03-05 Life Technologies, Inc. Support de culture de cellules de mammiferes exempt de serum
WO1998011203A1 (fr) 1996-09-13 1998-03-19 Novo Nordisk Biotech, Inc. Cellules presentant des mutations d'insertion d'adn produisant des quantites modifiees d'un polypeptide
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2310987A1 (fr) 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligands du tnf
WO1999047647A1 (fr) 1998-03-18 1999-09-23 Pharmacopeia, Inc. Cellules eucaryotes exprimant des genes de maniere stable a partir de multiples episomes transfectes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
JP2002027581A (ja) 2000-07-13 2002-01-25 Npl:Kk スピーカ
DE10036491A1 (de) 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
CN1596310A (zh) 2001-11-28 2005-03-16 桑多斯有限公司 产生重组多肽的方法
EP1488234A4 (fr) 2002-03-05 2006-05-24 Vitra Bioscience Inc Transfection de cellules multiplexees utilisant des supports codes
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005113770A1 (fr) 2004-05-13 2005-12-01 Institut Gustave Roussy Siarn anti-rhoa et -rhoc et compositions therapeutiques renfermant ceux-ci
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005046225B4 (de) 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
RU2608640C2 (ru) * 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN110251668A (zh) * 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
PH12013502531A1 (en) 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
WO2014041072A1 (fr) * 2012-09-14 2014-03-20 F. Hoffmann-La Roche Ag Procédé de production et de sélection de molécules comprenant au moins deux entités différentes et ses utilisations
UA119320C2 (uk) 2013-02-26 2019-06-10 Рош Глікарт Аг Активуюча т-клітини біспецифічна антигензв'язувальна молекула
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
BR112016006929A2 (pt) * 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
CA2932547C (fr) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Modules navettes de barriere hemato-encephalique monovalents
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
KR20170063946A (ko) 2014-10-08 2017-06-08 에프. 호프만-라 로슈 아게 Fap 및 dr5에 특이적인 이중특이성 항체와 화학요법제의 병용요법
SMT202100506T1 (it) 2015-10-02 2021-11-12 Hoffmann La Roche Anticorpi bispecifici specifici per pd1 e tim3
WO2017055542A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Also Published As

Publication number Publication date
JP7021245B2 (ja) 2022-02-16
RU2019131113A (ru) 2021-04-12
KR20210132207A (ko) 2021-11-03
CR20190397A (es) 2019-09-27
IL268470A (en) 2019-09-26
JP2022001059A (ja) 2022-01-06
WO2018162517A1 (fr) 2018-09-13
PE20191360A1 (es) 2019-10-01
CA3052357A1 (fr) 2018-09-13
RU2750721C2 (ru) 2021-07-01
NZ756132A (en) 2022-02-25
US20230129340A1 (en) 2023-04-27
CN110402253A (zh) 2019-11-01
JP2020509754A (ja) 2020-04-02
US20200216553A1 (en) 2020-07-09
MX2019010575A (es) 2019-10-15
SG11201908127WA (en) 2019-10-30
EP3592767A1 (fr) 2020-01-15
AU2018232698B2 (en) 2020-06-25
AU2018232698A1 (en) 2019-08-15
CL2019002521A1 (es) 2020-01-31
BR112019016970A2 (pt) 2020-04-07
RU2019131113A3 (fr) 2021-04-12
KR20190124270A (ko) 2019-11-04
CN110402253B (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
MA48723A (fr) Procédé de production d'anticorps multispécifiques
EP3677589A4 (fr) Procédé amélioré de production d'un conjugué anticorps-médicament
EP3433226A4 (fr) Procédé amélioré de production d'acide acrylique
EP3832305A4 (fr) Procédé de production d'exosomes
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3632550A4 (fr) Structure fonctionnelle et procédé de production pour structure fonctionnelle
EP3437493A4 (fr) Procédé de production de source d'arôme
EP3702346A4 (fr) Procédé de production d'hexafluorobutadiène
EP3632549A4 (fr) Structure fonctionnelle et procédé de production de structure fonctionnelle
EP3632541A4 (fr) Structure fonctionnelle et procédé de production de structure fonctionnelle
EP3527609A4 (fr) Procédé de production d'acide polyhydroxyalcanoïque
EP3632548A4 (fr) Structure fonctionnelle et procédé de production de structure fonctionnelle
MA48798A (fr) Procédé de production d'ozanimod
EP3613404A4 (fr) Procédé de production de film
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
EP3296282A4 (fr) Procédé de production d'hydrohalofluorooléfines
EP3388390A4 (fr) Procédé de production d'ozone
MA42423A (fr) Procédé de préparation d'un revêtement
EP3734620A4 (fr) Procédé de production d'électrode transparente
EP3633713A4 (fr) Procédé de production d'une structure et structure
EP3447042A4 (fr) Procédé de production de 1,2-dichlorohexafluorocyclopentène
EP3778560A4 (fr) Procédé de production d'acrylonitrile
EP3684757A4 (fr) Procédé de production d'alkylaromatiques
EP3466913A4 (fr) Procédé d'obtention de 1-octanol
EP3831804A4 (fr) Procédé de production de 1-acyloxy-2-méthyl-2-propène